Our current study builds on the findings with data indicating that PARP1 changes proteins in a cell-specific manner that includes modifications of proteins involved in transcription, messenger RNA metabolism, and protein translation, all of which are linked to the pathogenesis of human cancer.

And we are also working on how to improve on rapamycin therapies, understanding how resistance occurs, identifying new therapeutic targets for future drug development, and revealing new biomarkers to improve on current assays used to monitor disease progression, are all needed.